IL-FOURKITES
14.3.2024 12:31:31 CET | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites® today announced the promotion of Priya Rajagopalan to President of Product, Technology and Operations, as well as the appointment of Ron Richardson as Chief Revenue Officer (CRO). These appointments underscore FourKites’ focus on rapid growth and innovation, with an eye toward solving customers’ most pressing needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314808596/en/
FourKites promotes Priya Rajagopalan to President of Product, Technology and Operations and appoints Ron Richardson as Chief Revenue Officer to drive industry adoption and accelerate customer value (Photo: Business Wire)
Priya Rajagopalan leads FourKites’ Product, Engineering and Customer functions, with the goal of aligning customer needs and the company’s innovation engine to drive maximum customer value. Rajagopalan joined FourKites seven years ago as Chief Product Officer, bringing with her a wealth of experience in product management from various startups and public companies. Currently, Rajagopalan also serves on the Board of Directors of Brambles (ASX: BXB), the supply-chain logistics company operating across 60 countries through the CHEP brand. A testament to her industry contributions, she has been named an SDCE Pros to Know, and one of The Software Report’s Top 25 Software Product Executives.
Under Rajagopalan’s direction, FourKites has rolled out a number of industry-first product innovations, including real-time facility manager Dynamic Yard; end-to-end international ocean shipments tracker Dynamic Ocean; generative AI assistant Fin AI; patented AI-powered ETA forecaster Smart Forecasted Arrival; universal appointment scheduler Appointment Manager; and others.
“FourKites defined and created the supply chain visibility category, and innovating with customers has been, and continues to be part of our company’s DNA,” said Rajagopalan. “This alignment allows us to innovate and execute at even greater speed to ensure successful deployment and adoption across our customers."
Ron Richardson returns to FourKites as CRO, where he leads Sales, Partners and Alliances to drive FourKites’ global momentum. Ron recently served as CRO at OneRail, a solution that has redefined last-mile delivery, as well as CRO at Turvo, where he helped scale the company revenue and position it for a successful exit. Previously, Richardson was one of FourKites’ first employees, where he was instrumental in creating the real-time transportation visibility platform (RTTVP) category, building the business and closing some of the company’s earliest customer deals, including Coca-Cola, Nestlé and many more.
“I am thrilled to come back home to FourKites — returning to the market-leading company and the industry category I helped pioneer,” said Richardson. “I look forward to building on the momentum the team and I jump-started in the early years, driving growth and success among our Fortune 500 enterprise customers who continue to see massive value with the FourKites platform.”
“These promotions reflect our confidence in Priya’s and Ron’s leadership and their ability to propel FourKites to even greater heights,” said FourKites founder and CEO Mathew Elenjickal. “Priya’s unique blend of deep technical knowledge, innate leadership skills and collaborative approach has earned her admiration from industry leaders, investors and customers alike. Likewise, Ron brings deep industry experience, a strong track record as a successful CRO and, most importantly, vast knowledge of our existing customers and ecosystem. Under their leadership, we will continue to innovate, grow and solidify our position as the de-facto leader in the supply chain visibility space.”
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,500 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314808596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom